Cargando…

Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model

Spironolactone and furosemide, which are used to treat ascites associated with decompensated cirrhosis, are ineffective in treating refractory ascites. Hence, combination therapy with tolvaptan, a vasopressin V2 receptor antagonist, has been approved in Japan. Tolvaptan monotherapy and combination t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanabe, Norikazu, Takami, Taro, Fujisawa, Koichi, Matsumoto, Toshihiko, Yamamoto, Naoki, Sakaida, Isao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	the Society for Free Radical Research Japan 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525014/ https://www.ncbi.nlm.nih.gov/pubmed/28751810 http://dx.doi.org/10.3164/jcbn.16-122

Ejemplares similares

Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis
por: Iwamoto, Takuya, et al.
Publicado: (2016)

Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites
por: Goto, Atsushi, et al.
Publicado: (2014)

Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome
por: Meena, Jitendra, et al.
Publicado: (2020)

Impact of continued administration of tolvaptan on cirrhotic patients with ascites
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Addition of Tolvaptan Compared With Increased Dose of Furosemide in Heart Failure Patients With Chronic Kidney Disease Under Furosemide Treatment
por: Tanaka, Toshiki, et al.
Publicado: (2018)

Profiling of the circadian metabolome in thioacetamide‐induced liver cirrhosis in mice
por: Fujisawa, Koichi, et al.
Publicado: (2017)

Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites
por: Hosui, Atsushi, et al.
Publicado: (2021)

Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia
por: Wang, Shuzhen, et al.
Publicado: (2018)

The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2017)

Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites
por: Hirooka, Masashi, et al.
Publicado: (2022)

Metabolic Alterations in Spheroid-Cultured Hepatic Stellate Cells
por: Fujisawa, Koichi, et al.
Publicado: (2020)

An iron chelation-based combinatorial anticancer therapy comprising deferoxamine and a lactate excretion inhibitor inhibits the proliferation of cancer cells
por: Fujisawa, Koichi, et al.
Publicado: (2022)

Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure
por: Jujo, Kentaro, et al.
Publicado: (2016)

A new paradigm for the treatment of volume overload in heart failure-combined effect of tolvaptan with furosemide
por: Okamoto, Hiroshi
Publicado: (2013)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

Circadian variations in the liver metabolites of medaka (Oryzias latipes)
por: Fujisawa, Koichi, et al.
Publicado: (2016)

Evaluation of the effects of ascorbic acid on metabolism of human mesenchymal stem cells
por: Fujisawa, Koichi, et al.
Publicado: (2018)

Evaluation of the effects of L-carnitine on medaka (Oryzias latipes) fatty liver
por: Fujisawa, Koichi, et al.
Publicado: (2017)

Trans-portal hepatic infusion of cultured bone marrow-derived mesenchymal stem cells in a steatohepatitis murine model
por: Sasaki, Ryo, et al.
Publicado: (2020)

Seasonal variations in photoperiod affect hepatic metabolism of medaka (Oryzias latipes)
por: Fujisawa, Koichi, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Tolvaptan vs. furosemide‐based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA‐AHF)
por: Ng, Tien M.H., et al.
Publicado: (2020)

Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis
por: Sakaida, Isao, et al.
Publicado: (2016)

Risk and protective factors of acute kidney injury in decompensated cirrhotic patients with ascites on tolvaptan
por: Kogiso, Tomomi, et al.
Publicado: (2021)

Tolvaptan, hyponatremia, and heart failure
por: Zmily, Hammam D, et al.
Publicado: (2011)

Tolvaptan for the Treatment of Refractory Ascites
por: Kurosaki, Masayuki, et al.
Publicado: (2016)

Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease
por: Nagayama, Izumi, et al.
Publicado: (2019)

NUPR1 acts as a pro-survival factor in human bone marrow-derived mesenchymal stem cells and is induced by the hypoxia mimetic reagent deferoxamine
por: Matsunaga, Kazuhito, et al.
Publicado: (2019)

First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan
por: Tsuruya, Kota, et al.
Publicado: (2023)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016)

Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging
por: Fujisawa, Koichi, et al.
Publicado: (2015)

Correction: Evidence for a Role of the Transcriptional Regulator Maid in Tumorigenesis and Aging
por: Fujisawa, Koichi, et al.
Publicado: (2015)

Renoprotection by long‐term low‐dose tolvaptan in patients with heart failure and hyponatremia
por: Oka, Tatsufumi, et al.
Publicado: (2021)

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
por: Mizuno, Hiroki, et al.
Publicado: (2017)

Tolvaptan and its potential in the treatment of hyponatremia
por: Dixon, Megan B, et al.
Publicado: (2008)

V2 Receptor Antagonist; Tolvaptan
por: Yi, Joo-Hark, et al.
Publicado: (2011)

The management of polycystic liver disease by tolvaptan
por: Takenaka, Tsuneo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hfc7blgbngmk41cmth0qcmf4gr